Loading stock data…
PLRX
$1.20-0.02 (-1.64%)
After Hours$1.22+0.02 (+1.68%)· Last close May 1
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pliant Therapeutics, Inc. in the Healthcare sector is trading at $1.20. The stock is currently near its 52-week low of $1.09, remaining 15.5% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why PLRX maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 25) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.20
Potential Upside
5%
Whystock Fair Value$1.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecul...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$76.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-82.42%
Volume
Today's trading volume
374,035
Recent News
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference
Pliant Therapeutics (NASDAQ:PLRX) used its presentation at Oppenheimer’s 36th Annual Healthcare Conference to outline its strategic transition toward oncology following the discontinuation of its fibrosis efforts. Chief Executive Officer Bernard Coulie and Chief Financial Officer Keith Cummings high
3 Promising Penny Stocks With Market Caps Under $500M
As the U.S. stock market faces volatility with regional bank shares plummeting and bond yields hitting lows, investors are increasingly on the lookout for alternative opportunities. Penny stocks, though often overlooked and considered a relic of past trading days, remain relevant as they can offer surprising value in today's market landscape. When these smaller or newer companies are supported by strong financial health, they hold potential for significant returns; here we explore three such...
Align downgraded, NetEase upgraded: Wall Street's top analyst calls
Align downgraded, NetEase upgraded: Wall Street's top analyst calls
Penny Stocks To Watch With Market Caps Under $700M
As the U.S. stock market inches higher amid hopes for interest rate cuts, investors are closely monitoring economic indicators that could influence future Federal Reserve decisions. In this context, penny stocks—typically smaller or newer companies—remain a relevant investment area for those seeking unique opportunities outside the mainstream indices. While the term "penny stocks" might seem outdated, these investments can still offer significant value when backed by strong financials and...
3 Promising Penny Stocks With Market Caps Under $200M
Major indexes in the United States are experiencing mixed performances, with tech stocks rallying and bank stocks sliding following recent inflation data. In this context, penny stocks remain a compelling area of interest for investors looking for potential growth opportunities. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can offer significant value when backed by strong financials. Let's explore several such penny stocks that stand out for their...